Dr. John N Pritchard, Inspiring Strategies - Qepler Summits And Conferences

Dr. John N Pritchard

Independent Business Owner
Inspiring Strategies
Leicester, United Kingdom

From January 2011 - September 2018, John was CTO for Philips Respironics Drug Delivery, with global accountability for the development of products for the treatment of respiratory diseases. He is now a private consultant specialising in strategic approaches to developing respiratory devices, drugs and digital health.

At different stages in his career across 3 major pharmaceutical companies, he has been associated with the launch of 11 major products and at RDD in April 2018, John received the Charles Thiel award for outstanding research and discovery in respiratory drug delivery.

John has published widely in the field, as well as having served as Board member on various scientific and industry bodies. He has sat on a number of Advisory Boards and is currently a member of the UN Committee that makes recommendations on the essential uses of propellants.

Related Sessions:

Inhaled Drug Delivery
Summit 2019

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 23 May 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 23 May 2019
CASE STUDY: Re-thinking the opportunities for nebulised drugs.
  • Unmet medical needs in patients that would benefit from nebulised therapy
  • Potential commercial advantages from developing nebulized therapies ahead of the corresponding inhaler
  • Novel nebuliser technologies including the use of electronics to improve patient management
View Details

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 2: Friday, 06 August 2021
CASE STUDY: The climate is changing for metered dose inhalers.
  • Increases in global temperature are already having a significant impact on our climate. The hydrofluorocarbon (HFC) propellants used today in pressurized metered-dose inhalers (pMDIs) have global warming potential (GWP) many times that of carbon dioxide. This has prompted calls to switch patients to dry powder inhalers (DPIs)
  • Dry powder inhalers are often more expensive than the equivalent pMDI. A wholesale switch of reliever medications would lead to significant increases in the cost of these life-saving medications
  • At the same time, it is projected that there may be a 5-fold increase in the cost of pharmaceutical grade propellants in the next few years. This may lead to a price increase in reliever medication
  • At least two companies are now working to develop pMDIs using propellants which are potentially cheaper in the long-term and have much lower GWP
View Details